Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...

MSK radiation oncologist Dr. Nadeem Riaz and colleagues discovered that bacteria inside tumors can undermine the effects of immunotherapy. In cancer research, failure can lead to an important ...

Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, ...

HPV status, particularly combined p16 and HPV positivity, is vital for patient selection in de-escalation strategies for ...

Esophageal cancer occurring in patients with head and neck squamous cell carcinoma (HNSCC) represents a critical clinical challenge, as these secondary tumours notably worsen patient prognosis. Owing ...

Bacteria in head and neck tumor stimulate immunotherapy resistance by attracting immune cells and creating a shield.

HealthDay News — The rate of early termination or withdrawal in head and neck squamous cell carcinoma (HNSCC) clinical trials (CTs) has increased since 2000, with strategic decisions and poor ...

Panelists discuss how recurrent metastatic head and neck squamous cell carcinoma (HNSCC) manifests through symptoms such as persistent sore throat and neck lumps, with risk factors including tobacco ...

Head and neck cancer trials are frequently derailed before they can deliver answers. A new analysis suggests that the most ...